ArticleCancer research2026
Spatially Resolved Opto-Omics Uncovers Functional Microglial Subtypes in Brain Metastasis.
Article in Cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor microenvironment plays an important role in brain metastasis. To investigate microglial subtypes in the developing metastatic tumor microenvironment in this issue of Cancer Research, Tsuji and colleagues pioneer a cutting-edge approach for mapping the transcriptional fate of live, spatially identified cells using a method they call "opto-omics." Using a mouse model that enables microglia-specific transgenic expression of a photoconvertible fluorescent protein, the authors profile disease-associated microglia in spatial proximity to disseminated tumor cells (DTC) through intracerebral windows installed in the mouse skull. Microglia that spatially migrate to DTCs are photoconverted, and transcriptional profiling of these microglia reveals an overall enrichment in inflammatory gene programs with five distinct subpopulations corresponding to biological processes such as antigen presentation, type II IFN response, phagocytosis, TGFβ signaling, and tissue repair. This article describes a strategy to modulate the relative abundance of individual microglial subpopulations through pharmacologic perturbation of specific pathways, such as TGFβ, or through genetic ablation of "don't eat me" signals to reprogram protumor microglia. By developing opto-omics and demonstrating its functional integration with single-cell transcriptomics, the authors present a versatile platform for phenotypic profiling that may be applied in numerous areas of research. See related article by Tsuji et al., p. 1414.
Indexed as
Identifiers
41834497What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.